Urolift Pre-SBRT for Reduced Urinary Toxicity in Patients With BPH and Prostate Cancer.

Many patients may face long-term urinary side effects following stereotactic body radiation therapy (SBRT), including increased urinary frequency, dysuria, and nocturia. The investigator hypothesizes that Urolift, which represents a novel minimally invasive therapy, may reduce acute and long-term urinary toxicity and side effects of radiation therapy (SBRT).

Trial Details

NCT ID
NCT05148156
Phase
NA
Sponsor
Northwell Health
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Urolift
Locations (sample)
  • Syosset, New York, United States|40.82621,-73.50207

Key Eligibility Criteria

  • Subject is 50 - 99 years of age
  • Subject has provided informed consent
  • Subject has diagnosis of prostate cancer requiring SBRT
  • Subject is able to complete self-administered questionnaires

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →